噻唑烷二酮类药物对骨代谢影响的研究进展

发布时间：2018-03-07 16:48

本文选题：噻唑烷二酮类药物　切入点：骨代谢　出处：《河北医科大学》2017年硕士论文　论文类型：学位论文

【摘要】：噻唑烷二酮类药物(thiazolidinediones,TZDs)是一类可以增加胰岛素敏感性并改善胰岛素抵抗的口服降糖药物,主要通过激活过氧化物酶体增殖物激活型受体-γ(peroxisome proliferator-activated receptor gamma,PPAR-γ)而发挥作用,目前罗格列酮和吡格列酮是临床上最常应用的TZDs降糖药物。TZDs不仅能有效地控制2型糖尿病患者的血糖水平,还可用于治疗伴有胰岛素抵抗的代谢综合症。2型糖尿病是一种终身疾病需要长期治疗,在考虑降糖药物有效性的同时还要注意其安全性。然而,多项临床试验研究表明,TZDs能导致2型糖尿病患者骨量丢失、骨密度降低,甚至增加骨折风险。本文就TZDs对骨代谢的影响及其可能机制进行综述。
[Abstract]:Thiazolidinediones (TZDs) is an oral hypoglycemic drug that increases insulin sensitivity and improves insulin resistance, mainly by activating peroxisome proliferator activated receptor-纬 peroxisome proliferator-activated receptor gammama- 纬). At present rosiglitazone and pioglitazone are the most commonly used TZDs hypoglycemic drugs. Metabolic syndrome type 2 diabetes with insulin resistance can also be used as a life-long disease that requires long-term treatment, taking into account the efficacy of hypoglycemic drugs and their safety. A number of clinical trials have shown that TZDs can lead to loss of bone mass, decrease of bone mineral density and even increase the risk of fracture in patients with type 2 diabetes mellitus. This article reviews the effect of TZDs on bone metabolism and its possible mechanism.
【学位授予单位】：河北医科大学
【学位级别】：硕士
【学位授予年份】：2017
【分类号】：R96

【参考文献】